Clinical Trial Update: Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 trial is evaluating the addition of the immunotherapy atezolizumab to a Rituximab-Gemcitabine-Oxaliplatin regimen for relapsed/refractory and transfor…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Richter Syndrome
• Transformed Follicular Lymphoma to Diffuse Large B-cell Lymphoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• Gemcitabine (Gemcitabine)
• OXALIPLATIN (Oxaliplatin)
• Rituximab (rituximab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING